BV / Compliance
Plain-language about what we sell, to whom, and how.
Peptides sit in a fast-moving regulatory landscape. We'd rather over-disclose than handwave. This page is how Bioveris operates: who we sell to, what FDA status our products carry, how state restrictions are enforced, what records we keep, and how we communicate with regulators when asked.
This page is informational. It is not legal advice and does not replace the operating standards of your own license, practice agreement, or institutional review process. The binding terms of the relationship between you and Bioveris are in the Terms of Service and Privacy Policy.
Effective May 15, 2026 · Last updated May 15, 2026
§01 — Audience
Licensed practitioners and qualified research entities only.
Bioveris sells exclusively to verified licensed practitioners and qualified research entities authorized to procure research-grade and prescription-adjacent peptides within their jurisdiction.
In practice, an eligible account holder is one of:
- A U.S.-licensed physician (MD, DO), pharmacist, dentist, podiatrist, nurse practitioner (NP), physician assistant (PA), or naturopathic doctor (ND) where state law authorizes procurement, acting within the lawful scope of practice;
- A 503A or 503B compounding pharmacy or other entity authorized under state board of pharmacy rules and applicable federal law to receive bulk active pharmaceutical ingredients or research-grade peptides;
- A research institution, contract research organization, or qualified investigator authorized to procure research-use-only ("RUO") compounds for non-clinical scientific research.
How verification works:
- The applicant submits a current license or institutional authorization at account creation, along with organization details, principal place of practice, and a verifiable point of contact.
- A Bioveris compliance reviewer manually reviews the credential and cross-references it against the issuing state board (or, for research institutions, the institutional authorization on file).
- Pricing, product detail, and ordering function are not enabled for the account until the credential is verified and the account is approved.
- Active accounts are re-verified at credential expiration or, at our discretion, on a periodic cadence.
- We may, at our sole discretion, suspend or terminate access where eligibility cannot be re-verified, where a credential lapses, or where conduct on the account is inconsistent with eligibility.
We do not sell to unlicensed consumers, gyms, fitness retailers, supplement resellers, online marketplaces, or any party we cannot verify as eligible under this policy.
§02 — FDA status of the products we sell
Not all peptides are FDA-approved — and we surface which is which.
The peptides offered on Bioveris fall into one or more of the following regulatory postures, which are surfaced on each product detail page:
- FDA-approved active pharmaceutical ingredients (APIs) for compounding by 503A and 503B pharmacies operating under the relevant federal and state authorities;
- Generally legal-to-distribute research-grade peptidesintended for non-clinical research use only ("RUO"), where the practitioner or institution accepts the RUO designation at checkout; and
- Investigational compounds without FDA approval for general clinical use — including retatrutide and other comparable agents — which we sell under explicit on-screen disclaimer and attestation by the licensed practitioner.
Investigational compounds.Where a product is investigational, we surface it in the catalog with a compliance designation, require an on-screen disclaimer attestation before the SKU can be added to a cart, and log a timestamped record of that attestation against the practitioner's account. Investigational status means the compound has not been approved by the FDA, after the rigorous review described in 21 U.S.C. §355, to diagnose, treat, cure, mitigate, or prevent any disease or condition in the general patient population. It does not, by itself, render the compound unlawful for a licensed practitioner to procure for properly indicated, properly informed, properly documented clinical use within the practitioner's scope and the constraints of state pharmacy and medical-practice law — but that determination sits with the practitioner, not with Bioveris.
No medical claims. Statements on the Service have not been evaluated by the FDA. Bioveris does not represent that any product on the Service is intended to diagnose, treat, cure, mitigate, or prevent any disease or condition. We do not provide dosing guidance, indication recommendations, or patient-selection guidance, and nothing in our marketing, product literature, or support correspondence should be read as such.
§03 — State restrictions
Shipping is gated at checkout, not in transit.
Some U.S. states impose product-specific restrictions on certain peptides and related compounds, including but not limited to:
- State-level restrictions on the compounding or distribution of GLP-1 receptor agonists (semaglutide, tirzepatide, retatrutide, and analogs) that follow or anticipate FDA shortage-status changes;
- State-level restrictions on the distribution of growth hormone secretagogues; and
- General state pharmacy-board restrictions on bulk substance receipt by non-licensed-pharmacy entities.
The Service maintains a per-SKU, per-state allowlist that is updated as state-board rules and FDA guidance change. Orders to restricted destinations are blocked at checkout with an on-screen explanation — never discovered after a package leaves the facility. If you operate in a destination that the checkout flags and you believe a research authorization, institutional registration, or other exception applies, contact compliance@bioveris.co before placing the order.
We do not enumerate the restricted-state list on this page because it changes with FDA guidance and individual state board rulings, sometimes on weeks-to-months timescales. The authoritative list is the per-SKU restriction set surfaced at checkout.
§04 — Documentation and traceability
Lot, COA, chain-of-custody, and attestation records are retained for seven years.
Every order on Bioveris is documented with a permanent, customer-visible chain-of-custody record that includes:
- Lot number assigned at fulfillment;
- Certificate of Analysis (COA) from the qualifying laboratory, including HPLC purity, identity confirmation by mass spectrometry, and endotoxin testing (where applicable to the SKU);
- Carrier, tracking number, and delivery confirmation for each shipment;
- Compliance-disclaimer attestation(where the SKU is an investigational compound) tied to the practitioner's account, timestamped at confirmation; and
- Practitioner identifier (account ID and license-of-record at the time of order).
These records are visible to the practitioner from the customer portal for the life of the account and retained on our side for seven (7) years from the date of the order, consistent with conservative state pharmacy-board recordkeeping baselines.
If a regulator, state board, licensing body, or your own compliance department requests sourcing documentation for a product you procured, the trail starts on your order detail page and is export-ready in standard formats (PDF for the COA, CSV for the chain-of-custody record).
§05 — Audit and chain-of-custody integrity
Once a product leaves our hands, the chain of custody passes to you.
Once a product leaves our chain of custody (i.e., is tendered to the carrier and arrives at the practitioner's location), the chain of custody passes to the receiving practitioner. We do not accept returns of opened or temperature-sensitive product, because we cannot certify potency or sterility for a product that has been outside our environment.
If you become aware of a product-integrity concern — broken seal, temperature excursion in transit, visible vial damage, mismatched labeling, or COA discrepancy — stop using the product immediately, isolate the affected lot, and contact compliance@bioveris.co with photographs of the carton, packing materials, and product within 72 hours of delivery. We will, at our discretion and after review, replace the affected items, issue an account credit, or coordinate the return for QA investigation.
§06 — Adverse event reporting
Report suspected adverse events to us and, where applicable, to the FDA.
Bioveris is not a drug manufacturer subject to the mandatory MedWatch reporting requirements that apply to FDA-approved drug holders. We are, however, committed to good-faith cooperation with regulators when concerns arise.
For practitioners. Suspected adverse events associated with a product procured from Bioveris should be reported as follows:
- Notify Bioveris. Email compliance@bioveris.co with the order ID, the lot number(s), a clinical summary in non-identifying form (no PHI), and any photographs or supporting documentation. We log each report against the relevant lot and conduct an internal QA review.
- Report to the appropriate agency, where applicable. Where the practitioner determines the event meets the FDA MedWatch reporting threshold for the relevant compound or compounding pathway, report at www.fda.gov/medwatch or to the state board of pharmacy or medical board, as appropriate.
Patients. Patients of practitioner customers should report adverse events to their treating practitioner. Bioveris does not have a clinical relationship with patients and is not in a position to triage clinical concerns; that responsibility sits with the practitioner.
§07 — Compliance contact
How to reach us.
For any compliance question — eligibility, license verification, state restrictions, lot or COA documentation, adverse event reports, regulator inquiries — contact:
For legal-process service (subpoena, search warrant, court order):
Legal
Questions before you order?
Compliance questions go to compliance@bioveris.co. We respond within one business day.